Encouraging results from ProQR USH2A clinical trial
Biotechnology company ProQR has announced encouraging results from its phase 1/2 clinical trial of an innovative treatment for sight loss caused by faults in a specific section of the USH2A gene.
Search
Search results
e-Newsletter September 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK.